Leading COTA into the Next Chapter of Data-Driven Precision Oncology
I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies
In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.
To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences
COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
From Regulatory to RWD: A Journey to Improve Cancer Care with COTA
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
COTA Promotes Paige Whitney to Senior Vice President to Expand the Use of Real-World Data in Life Sciences
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
The Roadmap for Making Clinical Trials More Diverse and Representative
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
Real-World Data is Essential for Illuminating and Addressing Disparities in Care
RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
Study: 83% of Oncologists Believe Real-World Data Is Critical to Accelerating Cancer Research and Treatment
Oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials as well.
Real-World Data Champion Robert Califf Nominated for FDA Commissioner
Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.
COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition
Four abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.
